Literature DB >> 1953117

Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis.

D G Coit1, A Rogatko, M F Brennan.   

Abstract

Although pathologic nodal status is a major determinant of outcome in melanoma, there is substantial prognostic heterogeneity among node-positive patients. This study was undertaken to further clarify significant variables predicting survival in patients with melanoma metastatic to axillary or groin nodes. From 1019 patients with melanoma undergoing axillary or groin dissection between 1974 and 1984, the authors identified 449 patients with histologically positive nodes. Both univariate and multivariate analyses were performed using the Kaplan-Meier product limit method and the Cox model of proportional hazard regression. The major determinant of survival was pathologic stage (PS) according to the 1983 AJCC staging system. Three hundred fifty patients (78%) were classified PS-III (one nodal group involved), with a survival of 39% at 5 years and 32% at 10 years. Factors independently predictive of a favorable outcome in these patients were nontruncal primary site (p = 0.0002), microscopic nodal involvement (p = 0.001), number of positive nodes less than three (p = 0.003), and absence of extranodal disease (p = 0.01). Ninety-nine patients (22%) were classified PS-IV, 51 with two nodal stations involved (N2), 25 with intransit disease and one nodal station involved (N2), 7 with extraregional soft tissue metastases (M1), and 16 with visceral metastases (M2). Survival for PS-IV patients was 9% at 5 and 10 years, respectively. Within PS-IV, factors independently predictive of a more favorable outcome were the absence of extranodal disease (p = 0.0001), female sex (p = 0.03), and a long interval from diagnosis to lymph node dissection (p = 0.04). These factors were incorporated into a model predicting relative risk of death from disease for both PS-III and PS-IV patients, separating patients into groups at high, intermediate, and low risk of recurrence after lymphadenectomy.

Entities:  

Mesh:

Year:  1991        PMID: 1953117      PMCID: PMC1358620          DOI: 10.1097/00000658-199111000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  Biostatistical basis of elective node dissection for malignant melanoma.

Authors:  J G Fortner; J Woodruff; D Schottenfeld; B Maclean
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

2.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

3.  Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.

Authors:  M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; S A Rosenberg
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Regional lymph node metastases and the level of invasion of primary melanoma.

Authors:  E C Holmes; W Clark; D L Morton; F R Eilber; A J Bochow
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

6.  Adjuvant chemotherapy combination of vinblastine, actinomycin D, Bleomycin, and Chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor.

Authors:  D Vugrin; W F Whitmore; E Cvitkovic; H Grabstald; P Sogani; W Barzell; R B Golbey
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

7.  Prognostic value of lymph node dissection in malignant melanoma.

Authors:  C P Karakousis; M K Seddiq; R Moore
Journal:  Arch Surg       Date:  1980-06

8.  A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

9.  Late recurrence of malignant melanoma. Analysis of 168 patients.

Authors:  N J Crowley; H F Seigler
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

10.  Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes.

Authors:  C L Day; A J Sober; R A Lew; M C Mihm; T B Fitzpatrick; A W Kopf; M N Harris; S L Gumport; J W Raker; R A Malt; F M Golomb; A B Cosimi; W C Wood; P Casson; S Lopransi; F Gorstein; A Postel
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

View more
  19 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

2.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

Review 3.  Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update.

Authors:  Isabel Callejo Peixoto; José Meneses e Sousa
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

4.  Multiplying therapies and reducing toxicity in metastatic melanoma.

Authors:  Paul R Massey; Vinay Prasad; William D Figg; Tito Fojo
Journal:  Cancer Biol Ther       Date:  2015-05-27       Impact factor: 4.742

5.  Robotic transperitoneal ilioinguinal pelvic lymphadenectomy for high-risk melanoma: an update of 18-month follow-up.

Authors:  Antonio Pellegrino; Gianluca Raffaello Damiani; Davide Strippoli; Fabrizio Fantini
Journal:  J Robot Surg       Date:  2014-03-22

6.  Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.

Authors:  Rebekah R White; Wilma E Stanley; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

7.  Groin dissection in malignant melanoma.

Authors:  C P Karakousis; D L Driscoll; B Rose; D L Walsh
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

8.  Parametric modeling of localized melanoma prognosis and outcome.

Authors:  Shouluan Ding; Seng-Jaw Soong; Hui-Yi Lin; Renee Desmond; Charles M Balch
Journal:  J Biopharm Stat       Date:  2009-07       Impact factor: 1.051

9.  Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy.

Authors:  Hassan A Aziz; Brian R Gastman; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2015-05-06

10.  Wound complications after inguinal lymph node dissection for melanoma: is ACS NSQIP adequate?

Authors:  Carly E Glarner; David Y Greenblatt; Robert J Rettammel; Heather B Neuman; Sharon M Weber
Journal:  Ann Surg Oncol       Date:  2013-01-22       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.